Receptors, Neurokinin-1

• 

  Subject Areas on Research

  • A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas. 
  • A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting. 
  • Agonist-induced internalization of the substance P (NK1) receptor expressed in epithelial cells. 
  • Alterations in receptors for sensory neuropeptides in human inflammatory bowel disease. 
  • Attenuation of acid induced oesophagitis in VR-1 deficient mice. 
  • Capsaicin vanilloid receptor-1 mediates substance P release in experimental pancreatitis. 
  • Characterization of GRK2-catalyzed phosphorylation of the human substance P receptor in Sf9 membranes. 
  • Characterization of antibodies to the rat substance P (NK-1) receptor and to a chimeric substance P receptor expressed in mammalian cells. 
  • Characterization of differences between rapid agonist-dependent phosphorylation and phorbol ester-mediated phosphorylation of human substance P receptor in intact cells. 
  • Clinical experience with substance P receptor (NK1) antagonists in depression. 
  • Developmental expression of neurokinin A and functional neurokinin-2 receptors in lung. 
  • Differential expression of substance P receptors in patients with Crohn's disease and ulcerative colitis. 
  • Differential expression of two isoforms of the neurokinin-1 (substance P) receptor in vivo. 
  • Direct observation of substance P-induced internalization of neurokinin 1 (NK1) receptors at sites of inflammation. 
  • Ethnomedicinally selected plants as sources of potential analgesic compounds: indication of in vitro biological activity in receptor binding assays. 
  • Extrinsic surgical denervation ameliorates TNBS-induced colitis in rats. 
  • Human substance P receptor expressed in Chinese hamster ovary cells directly activates G(alpha q/11), G(alpha s), G(alpha o). 
  • Human substance P receptor expressed in Sf9 cells couples with multiple endogenous G proteins. 
  • Human substance P receptor lacking the C-terminal domain remains competent to desensitize and internalize. 
  • Human substance P receptor undergoes agonist-dependent phosphorylation by G protein-coupled receptor kinase 5 in vitro. 
  • Increased substance P receptor expression by blood vessels and lymphoid aggregates in Clostridium difficile-induced pseudomembranous colitis. 
  • Localisation of NK1 receptor immunoreactivity to neurons and interstitial cells of the guinea-pig gastrointestinal tract. 
  • Localization of substance P NK-1 receptors in rat tongue. 
  • Management of postdischarge nausea and vomiting after ambulatory surgery. 
  • Mechanisms of desensitization and resensitization of G protein-coupled neurokinin1 and neurokinin2 receptors. 
  • Mild Traumatic Brain Injury in Mice Beneficially Alters Lung NK1R and Structural Protein Expression to Enhance Survival after Pseudomonas aeruginosa Infection. 
  • Molecular determinants underlying the formation of stable intracellular G protein-coupled receptor-beta-arrestin complexes after receptor endocytosis*. 
  • Morphological characterization of substance P receptor-immunoreactive neurons in the rat spinal cord and trigeminal nucleus caudalis. 
  • Neurokinin subtype receptors mediating substance P contraction in immature rabbit airways. 
  • Neurokinin-1 (NK-1) receptor is required in antigen-induced cystitis. 
  • Neurokinin-1 receptor enhances TRPV1 activity in primary sensory neurons via PKCepsilon: a novel pathway for heat hyperalgesia. 
  • Neuromodulation mediated by neurokinin-1 subtype receptors in adult rabbit airways. 
  • Nuclear factor kappa B mediates lipopolysaccharide-induced inflammation in the urinary bladder. 
  • Oncogenic and metastatic properties of preprotachykinin-I and neurokinin-1 genes. 
  • Phosphorylation and desensitization of neurokinin-1 receptor expressed in epithelial cells. 
  • Rapid endocytosis of a G protein-coupled receptor: substance P evoked internalization of its receptor in the rat striatum in vivo. 
  • Real-time visualization of the cellular redistribution of G protein-coupled receptor kinase 2 and beta-arrestin 2 during homologous desensitization of the substance P receptor. 
  • Receptor binding sites for cholecystokinin, galanin, somatostatin, substance P and vasoactive intestinal polypeptide in sympathetic ganglia. 
  • Receptor binding sites for substance P, but not substance K or neuromedin K, are expressed in high concentrations by arterioles, venules, and lymph nodules in surgical specimens obtained from patients with ulcerative colitis and Crohn disease. 
  • Receptor endocytosis and dendrite reshaping in spinal neurons after somatosensory stimulation. 
  • Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder. 
  • Rolapitant for the prevention of postoperative nausea and vomiting: a prospective, double-blinded, placebo-controlled randomized trial. 
  • Signal transduction through substance P receptor in human glioblastoma cells: roles for Src and PKCdelta. 
  • Sprouting of substance P-expressing primary afferent central terminals and spinal micturition reflex NK1 receptor dependence after spinal cord injury. 
  • Substance P (NK1) receptor immunoreactivity on endothelial cells of the rat tracheal mucosa. 
  • Substance P activation of enteric neurons in response to intraluminal Clostridium difficile toxin A in the rat ileum. 
  • Substance P and its receptor neurokinin 1 expression in asthmatic airways. 
  • Substance P and substance K receptor binding sites in the human gastrointestinal tract: localization by autoradiography. 
  • Substance P binding sites on intestinal lymphoid aggregates and blood vessels in inflammatory bowel disease correspond to authentic NK-1 receptors. 
  • Substance P dependence of endosomal fusion during bladder inflammation. 
  • Substance P receptor binding sites are expressed by glia in vivo after neuronal injury. 
  • Substance P receptor mediated maintenance of chronic inflammation in EAE. 
  • Substance P receptors on canine chief cells: localization, characterization, and function. 
  • Synaptic relationship between substance P and the substance P receptor: light and electron microscopic characterization of the mismatch between neuropeptides and their receptors. 
  • Synthesis and NK(1)/NK(2) binding activities of a series of diacyl-substituted 2-arylpiperazines. 
  • The N-terminal domain of substance P is required for complete homologous desensitization but not phosphorylation of the rat neurokinin-1 receptor. 
  • The NK(1) receptor antagonist WIN51708 reduces sensitization after chronic cocaine. 
  • The dynamics of bone marrow stromal cells in the proliferation of multipotent hematopoietic progenitors by substance P: an understanding of the effects of a neurotransmitter on the differentiating hematopoietic stem cell. 
  • The effects of toluene diisocyanate and of capsaicin on human bronchial smooth muscle in vitro. 
  • The evaluation of drug rechallenge: the casopitant Phase III program. 
  • The localization of sensory nerve fibers and receptor binding sites for sensory neuropeptides in canine mesenteric lymph nodes. 
  • The role of the amino-terminal domain of tachykinins in neurokinin-1 receptor signaling and desensitization. 
  • The substance P receptor, which couples to Gq/11, is a substrate of beta-adrenergic receptor kinase 1 and 2.